secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kiniksa Pharmaceuticals International, plc (KNSA)
CIK:        0001730430
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001104659-25-002858
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M
--------------------------------------------------------------------------------

- ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.
- 2025 ARCALYST net product revenue guidance: $560M to $580M.
- Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.
- Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.
- Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/0001104659-25-002858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730430/000110465925002858/tm252986d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-002858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer